Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07213791 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

A Phase 1 study of Breast Neoplasms and Cholangiocarcinoma, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
241
Enrollment target
20
Study locations

NCT07213791 is a Phase 1 study of Breast Neoplasms and Cholangiocarcinoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 241 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07213791, a Phase 1 study of Breast Neoplasms and Cholangiocarcinoma, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
241 participants
Enrollment target
20
Study locations

Study Summary

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Conditions Studied

Breast Neoplasms Cholangiocarcinoma Colorectal Neoplasms Ovarian Neoplasms Esophageal Neoplasms Stomach Neoplasms Pancreatic Intraductal Neoplasms

Interventions

  • DRUG LY4337713

Study Locations (20)

California

  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • Stanford University Medical Center - Stanford

Florida

  • Biogenix Molecular, LLC - Miami
  • Moffitt - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • BAMF Health Inc. - Grand Rapids

New York

  • New York University (NYU) Clinical Cancer Center - New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Fox Chase Cancer Center - Philadelphia

Texas

  • Texas Oncology - DFW (Sammons CC) - Dallas
  • Baylor College of Medicine - Houston

Indiana

  • Indiana University (IU) School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2025-10-22
Est. Completion 2033-03
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07213791

The ClinicalTrials.gov registry entry for NCT07213791 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (57% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which LY4337713 is the first listed.

NCT07213791 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07213791 about?

NCT07213791 is a clinical study titled "A Study of LY4337713 in Participants With FAP-Positive Solid Tumors". This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. ...

What is the current status of trial NCT07213791?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2025-10-22. Estimated completion is 2033-03.

What conditions does trial NCT07213791 study?

This clinical trial studies the following conditions: Breast Neoplasms, Cholangiocarcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Esophageal Neoplasms.

What interventions are being tested in trial NCT07213791?

The interventions under investigation include: LY4337713 (DRUG).

Who is sponsoring clinical trial NCT07213791?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07213791 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

Cholangiocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.